HD-PLC-ALLIANCE
16.3.2021 07:02:09 CET | Business Wire | Press release
In order to integrate the latest improvements in speed and range of the HD-PLC*1 technology promoted by HD-PLC Alliance*2 , the Alliance has proposed the specifications of the next generation technology to the IEEE Standards Association*3 . To the great satisfaction of the Alliance members, recently published IEEE 1901-2020 Standard includes the latest HD-PLC features that provide higher speed, longer range wired communications over existing metal wires (control cable, coaxial cable, power cable, etc.).
Compared with wireless communication systems, HD-PLC enables more secure, stable and reliable communications. Furthermore, the use of existing cables allows a network infrastructure to cover not only indoors such as homes, buildings and factories but also outdoors extending several kilometers.
Mr. Yoshiyuki Miyabe, Senior Adviser of HD-PLC Alliance and Senior Managing Executive Officer of Panasonic Corporation, has sent a message, “Our company and HD-PLC Alliance have developed the HD-PLC technology cooperatively, which is now published as IEEE 1901-2020 standard. We anticipate this standardization will help make HD-PLC a breakthrough technology for the coming era of IoT. Making the most of this result for various products and business solutions for the future, we endeavor to further support innovation and advancement of the technology to provide new values to our customers.”
HD-PLC Alliance devotes its efforts to promote the technology through a certification program and logo. The test environment is being updated to offer the current third-generation communication compatibility services as well as upcoming fourth generation interoperability certification services compliant with IEEE 1901-2020.
On March 18, 2021, a webinar*4 on this technology will be held, organized by IEEE SA and HD-PLC Alliance. Also, please visit our renewed website.*5
Related Information:
HD-PLC Alliance members Press Release
[Panasonic Corporation]
Licensing IP Core for Semiconductors Complying with the IEEE 1901–2020 International Standard
https://news.panasonic.com/global/press/data/2021/03/en210316-2/en210316-2.html
[Socionext Inc.]
Socionext Agrees With MIRAIT, MMD, And Nuri Telecom On Next-Generation Long-Distance Power Line Communications For Verification And Social Implementation
https://www.socionext.com/en/pr/sn_pr20210309_01e.pdf
(Note) |
|
*1: |
HD-PLC™: A registered trademark or trademark of Panasonic Corporation in Japan and other countries. |
*2: |
HD-PLC Alliance: Established on September 25, 2007 with the aim to expand the use of High-definition Power Line Communication (HD-PLC) and to ensure communication compatibility. |
*3: |
IEEE Standards Association: Standards association within the Institute of Electrical and Electronics Engineers (IEEE) |
IEEE 1901-2020 standard: https://standards.ieee.org/standard/1901-2020.html |
|
*4: |
IEEE SA and HD-PLC Alliance Webinar March 2021 |
|
Subtitle: Home networking, Industrial and Building automation through HD-PLC (High-Speed Powerline Communication) |
Learn more: https://standards.ieee.org/events/index.html |
|
*5: |
HD-PLC Alliance Homepage: https://hd-plc.org/ |
View source version on businesswire.com: https://www.businesswire.com/news/home/20210315005273/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom